{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:41:16Z","timestamp":1789612876994,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01-HL-081616"],"award-info":[{"award-number":["U01-HL-081616"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01-HL-081649"],"award-info":[{"award-number":["U01-HL-081649"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.amjcard.2020.12.075","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T18:41:40Z","timestamp":1610649700000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-7324","authenticated-orcid":false,"given":"Nathan D.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanglu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auris","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.12.075_bib0001","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a) resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pcad.2016.07.005","article-title":"The re-emergence of lipoprotein(a) in a broader clinical arena","volume":"59","author":"Tsimikas","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0004","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a)","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardio"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0005","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0006","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0007","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamacardio.2017.3833","article-title":"Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial","volume":"3","author":"Schwartz","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0008","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL-cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0009","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0011","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglyceride and impact on global health outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0012","doi-asserted-by":"crossref","unstructured":"O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, Desai NR, Solomon SD, Domanski M, Arai K, Chiuve SE, Cannon CP, Sacks FM, Sabatine MS. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 2014;63:520-527.","DOI":"10.1016\/j.jacc.2013.09.042"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0013","doi-asserted-by":"crossref","unstructured":"Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association. J Clin Lipidol2019;13:374-392.","DOI":"10.1016\/j.jacl.2019.04.010"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0014","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J.2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Circulation 2019; 139(25):e1182-e1186]. Circulation2019;139:e1082-e1143.","DOI":"10.1161\/CIR.0000000000000624"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0015","doi-asserted-by":"crossref","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020;75:133-144.","DOI":"10.1016\/j.jacc.2019.10.057"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0016","doi-asserted-by":"crossref","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020;382:244-255.","DOI":"10.1056\/NEJMoa1905239"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0017","doi-asserted-by":"crossref","unstructured":"Zhang Y, Jin JL, Cao YX, Zhang HW, Guo YL, Wu NQ, Zhu CG, Gao Y, Hua Q, Li YF, Xu RX, Li JJ. Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. Cardiovasc Diabetol 2020;19:111.","DOI":"10.1186\/s12933-020-01083-8"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0018","doi-asserted-by":"crossref","unstructured":"Saeed A, Sun W, Agarwala A, Virani SS, Nambi V, Coresh J, Selvin E, Boerwinkle E, Jones PH, Ballantyne CM, Hoogeveen RC. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the atherosclerosis risk in communities study. Atherosclerosis2019;282:52-56.","DOI":"10.1016\/j.atherosclerosis.2018.12.022"},{"key":"10.1016\/j.amjcard.2020.12.075_bib0019","doi-asserted-by":"crossref","unstructured":"Klimchak AC, Patel MY, Iorga SR, Kulkarni N, Wong ND. Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States. Am J Prev Cardiol 2020; 1:100010.","DOI":"10.1016\/j.ajpc.2020.100010"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291492100031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291492100031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:36:50Z","timestamp":1757572610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291492100031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":19,"alternative-id":["S000291492100031X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.075","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}